Home > > > Report Detail

China Blood Product Industry Report, 2020-2026

Publisher Name :
Date: 21-Jan-2020
No. of pages: 160

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimbursement from the national medical insurance system. In 2019, the lot release of blood products in China increased further and reached 89.89 million bottles with a year-on-year surge of 21.6%.

Elaborately, the lot release of human albumin rose 17.2% on an annualized basis, making up 58.9%; that of human rabies immunoglobulin soared by 42.9% and accounted for 13.6%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 13% in the total showed a year-on-year increase of 14.1%; and that of human tetanus immunoglobulin surged by 76.7% and occupied 6.9%.

Other products had small shares, such as human fibrinogen, three kinds of special immunoglobulin, human prothrombin complex, human coagulation factor Ⅷ, particularly coagulation factor category as the lifesaving drug to the victims of hemophilia are often in short supply largely because of the shortage of plasma raw materials domestically as well as the low utilization of plasma.

As the prices of blood products are decontrolled and new plasma stations accelerate to be constructed in recent years, plasma collection in China has been growing year after year, reaching 8,600 tons or more in 2018 with a year-on-year increase of 7.5%. Of all, Beijing Tiantan Biological Products Co., Ltd in possession of 57 plasma stations ranked first by plasma collection up to 1,568.7 tons, a 16.5% share of the total, and its production efficiency gets improved significantly after an asset restructuring.

There are now about thirty blood product enterprises in China, but they are small-sized without rich product portfolios. The industry desires to be concentrated. It is starting from 2008 that the leading players staged mergers and acquisitions and have been developing apace mainly through M&A whilst independently building plasma stations. Meanwhile, some influential companies have turned their attention to overseas resources and good mode and have been actively exploring overseas markets through acquisitions and introducing state-of-the-art technologies from abroad. Undoubtedly, the Chinese market of blood products will get ever concentrated.

What’s more, leading competitors beef up research and development of new products successively and strive to improve comprehensive utilization of plasma. A case in point is the coagulation factorⅧ. Only a few Chinese companies such as China Biologic Products Holdings, Inc., Hualan Biological Engineering Co., Ltd., Shanghai RAAS Blood Products Co., Ltd and Green Cross China are competent to produce the coagulation factorⅧ, but the peers including Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Southern Shuanglin Bio-Pharmacy Co., Ltd. (formerly known as Zhenxing Biopharmaceutical & Chemical Co., Ltd.), Wuhan ZhongyuanRuide Biological Products Co., Ltd., Beijing Bohui Innovation Technology Co., Ltd., Shenzhen Weiguang Biological Products Co., Ltd and Nanyue Biopharming Co., Ltd. are chasing hard and sparing no efforts in the development of the coagulation factorⅧ.

China Blood Product Industry Report, 2020-2026 covers the following:


  • Blood product market (policy, status quo, market structure, supply & demand, market size and competitive pattern);

  • Blood product market segments (development, bidding price, competitive landscape);

  • 13 blood product companies (operation, revenue structure, gross margin and blood product business, etc.);

  • Summary and forecast.

China Blood Product Industry Report, 2020-2026

Table of Contents

1. Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. China Blood Product Market
2.1 Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. China Blood Product Market Segments
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Bid Price
3.2.3 Competition Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Bid Price
3.3.3 Competition Pattern
3.3.4 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Bid Price
3.4.3 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Bid Price
3.5.3 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Bid Price
3.6.3 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Bid Price
3.7.3 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Bid Price
3.8.3 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.5 Guangdong Shuanglin Bio-Pharmacy
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product Co., Ltd.
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Development of the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry

List of Charts

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2019
Blood Product Structure in China (by Lot Release Volume), 2014-2019
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2019
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
Plasma Collection Volume and YoY Growth Rate in China, 2008-2019
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2019
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Dec. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2019
Net Income of Major Blood Product Enterprises in China, 2013-2019
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2019
Market Share of China Blood Product Industry (by Enterprise), 2018
Market Share of China Blood Product Industry (by Enterprise), 2019
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2019
Market Share of Human Albumin in China (by Lot Release Volume), 2018
Market Share of Human Albumin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2019
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2019
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2019
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Prothrombin Complex in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2019
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2019
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2019
Cases, Deaths and Mortality of Rabies in China, 2013-2019
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2019
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2014-2019
Revenue Breakdown of CBPO (by Product), 2012-2019
Revenue Structure of CBPO (by Product), 2012-2019
Gross Margin of CBPO, 2012-2019
R&D Costs and % of Total Revenue of CBPO, 2012-2019
CBPO’s Products under Research and R&D Process by the end of 2018
Main R&D Pipeline Products of Beijing TianXinFu Medical Appliance
Lot Release Volume of Blood Products of CBPO, 2016-2019
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Dec.2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2019
Revenue and Net Income of Hualan Biological Engineering, 2013-2019
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2019
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2019
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2019
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2019
Category and Specification of Blood Products of Hualan Biological Engineering
Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2018
Revenue of Blood Products of Hualan Biological Engineering, 2013-2019
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2019
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2019
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2019
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2019
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2019
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2019
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2019
R&D Costs of Shanghai RAAS Blood Products, 2013-2019
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2018
Revenue and Net Income of Tiantan Biological Products, 2013-2019
Revenue Breakdown of TIANTANBIO (by Product), 2013-2019
Revenue Structure of TIANTANBIO (by Product), 2013-2019
Gross Margin of TIANTANBIO (by Product), 2013-2018
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2019
R&D Input of Major Projects of TIANTANBIO, 2018
Progress of Major R&D Projects of TIANTANBIO, by the End of 2018
TIANTANBIO’s Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TIANTANBIO, 2018
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2019
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2019
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2019
Gross Margin of Shuanglin Bio-Pharmacy, 2013-2019
R&D Costs and % of Total Revenue of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2019
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2018
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2019
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2019
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2019
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2019
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2019H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2019H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2019
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2019
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2019
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2019
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2019
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2019H1
Major Blood Products of Beijing Bohui Innovation Technology
Financials of Beijing Bohui Innovation Technology, 2017-2019
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2019
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Plasmapheresis Centers of Wuhan ZhongyuanRuide Biological Products, as of Dec.2019
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2019
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2019
Plasmapheresis Centers of Nanyue Biopharming, as of Dec.2019
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2019
Plasma Collection Volume and YoY Change in China, 2018-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2019
Population Aged above 60 as a Percentage of Total Population in China, 2009-2018

  • Global Cytokine Inhibitor Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
  • Global Microbial Growth Media Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc. The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030. The market for microbial growth media is essential in microbiology and biotechnology rese......
  • Global Protein Biochip Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 92
    Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser. The global Protein Biochip market was valued at US$ 145 million i......
  • Global Isothermal Nucleic Acid Amplification Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 103
    Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction. T......
  • Global Microfluidics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 122
    According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
  • Global Cytokines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period. The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
  • Global Western Blot Imagers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period. The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
  • Global Procalcitonin Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 125
    According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs